PRANDIN
What it isMeglitinide closing the beta-cell KATP channel; postprandial hyperglycemia in type 2 diabetes.
Why this oneMeal-linked dosing can be omitted with a skipped meal, reducing prolonged hypoglycemia compared with sulfonylureas.
What limits itFrequent meal-time dosing burdens adherence. Gemfibrozil is contraindicated because CYP2C8 inhibition can cause severe hypoglycemia.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Type 2 diabetes | Adults, HbA1c <8% | 0.5 mg before each meal | 0.5-4 mg before meals | 16 mg/day |
| Type 2 diabetes | Adults, HbA1c >=8% | 1-2 mg before each meal | 0.5-4 mg before meals | 16 mg/day |
Titration At least 1 week between dose adjustments
Renal Severe impairment (CrCl 20-40): start 0.5 mg before each meal; CrCl <20/dialysis not studied
Hepatic Use caution; longer intervals between dose adjustments; higher hypoglycemia risk
Dose before each meal (2-4x daily)
Pregnancy Limited data show no clear drug-associated risk; poorly controlled diabetes carries risk
Lactation Not recommended when breastfeeding
NO BOXED WARNINGS
Principal riskHypoglycemia; contraindicated with gemfibrozil
Cost, est. cash$5–$150/month
Generic entry2013
Legacy pregnancy categoryMultiple / indication-, trimester- or formulation-dependent
Defining liabilityAgent-specific hypoglycemia, ketoacidosis, volume, renal or gastrointestinal toxicity.

Open Repaglinide in the interactive console ↗
